Empagliflozin in Heart Failure with a Preserved Ejection FractionStefan D. Anker, Milton Packer, Béla Merkely et al.|New England Journal of Medicine|2021Cited by 4.6k
Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart FailureAlessandra Dei, Gregg C. Fonarow, Sadiya S. Khan et al.|JACC Heart Failure|2015Cited by 409
Prevalence and Prognostic Impact of Non-Cardiac Co-Morbidities in Heart Failure Outpatients with Preserved and Reduced Ejection Fraction: A Community-Based StudyAndrea Di Lenarda, Michele Senni, Giulia Barbati et al.|European Journal of Heart Failure|2018Cited by 174
Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved TrialStefan D. Anker, Milton Packer, Javed Butler et al.|European Journal of Heart Failure|2020Cited by 135
Management of Heart Failure Patients with COVID-19: A Joint Position Paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of CardiologyYuhui Zhang, Marco Metra, Andrew J.S. Coats et al.|European Journal of Heart Failure|2020Cited by 113